A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

Summary

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 36 weeks.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Irritable Bowel Syndrome
• Constipation

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Eli Lilly and Company

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites